These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
274 related articles for article (PubMed ID: 37834474)
41. Design, synthesis, biological evaluation and molecular docking study of novel thieno[3,2-d]pyrimidine derivatives as potent FAK inhibitors. Wang R; Yu S; Zhao X; Chen Y; Yang B; Wu T; Hao C; Zhao D; Cheng M Eur J Med Chem; 2020 Feb; 188():112024. PubMed ID: 31923858 [TBL] [Abstract][Full Text] [Related]
42. Design, Synthesis, and Antiproliferative Activity of New 5-Chloro-indole-2-carboxylate and Pyrrolo[3,4- Al-Wahaibi LH; Mohammed AF; Abdelrahman MH; Trembleau L; Youssif BGM Molecules; 2023 Jan; 28(3):. PubMed ID: 36770936 [TBL] [Abstract][Full Text] [Related]
43. Novel pyrazolo[3,4-d]pyrimidines: design, synthesis, anticancer activity, dual EGFR/ErbB2 receptor tyrosine kinases inhibitory activity, effects on cell cycle profile and caspase-3-mediated apoptosis. Maher M; Kassab AE; Zaher AF; Mahmoud Z J Enzyme Inhib Med Chem; 2019 Dec; 34(1):532-546. PubMed ID: 30688116 [TBL] [Abstract][Full Text] [Related]
44. Design, synthesis and biological evaluation of new series of hexahydroquinoline and fused quinoline derivatives as potent inhibitors of wild-type EGFR and mutant EGFR (L858R and T790M). Shaheen MA; El-Emam AA; El-Gohary NS Bioorg Chem; 2020 Dec; 105():104274. PubMed ID: 33339080 [TBL] [Abstract][Full Text] [Related]
45. Structural modifications on indole and pyrimidine rings of osimertinib lead to high selectivity towards L858R/T790M double mutant enzyme and potent antitumor activity. Liu Q; Luo Y; Li Z; Chen C; Fang L Bioorg Med Chem; 2021 Apr; 36():116094. PubMed ID: 33667898 [TBL] [Abstract][Full Text] [Related]
46. Cytotoxic and Apoptotic Effects of Novel Pyrrolo[2,3-d]Pyrimidine Derivatives Containing Urea Moieties on Cancer Cell Lines. Kilic-Kurt Z; Bakar-Ates F; Karakas B; Kütük Ö Anticancer Agents Med Chem; 2018; 18(9):1303-1312. PubMed ID: 29866023 [TBL] [Abstract][Full Text] [Related]
47. Recruitment of hexahydroquinoline as anticancer scaffold targeting inhibition of wild and mutants EGFR (EGFR Abo Al-Hamd MG; Tawfik HO; Abdullah O; Yamaguchi K; Sugiura M; Mehany ABM; El-Hamamsy MH; El-Moselhy TF J Enzyme Inhib Med Chem; 2023 Dec; 38(1):2241674. PubMed ID: 37548154 [TBL] [Abstract][Full Text] [Related]
48. Exploration of thiazolidine-2,4-diones as tyrosine kinase inhibitors: Design, synthesis, ADMET, docking, and antiproliferative evaluations. Aziz NAAM; George RF; El-Adl K; Mahmoud WR Arch Pharm (Weinheim); 2023 Mar; 356(3):e2200465. PubMed ID: 36403198 [TBL] [Abstract][Full Text] [Related]
49. Design, synthesis and molecular docking of new fused 1 Belal A; Abdel Gawad NM; Mehany ABM; Abourehab MAS; Elkady H; Al-Karmalawy AA; Ismael AS J Enzyme Inhib Med Chem; 2022 Dec; 37(1):1884-1902. PubMed ID: 35801486 [TBL] [Abstract][Full Text] [Related]
50. Design, synthesis, anticancer evaluation, molecular docking and cell cycle analysis of 3-methyl-4,7-dihydropyrazolo[1,5-a]pyrimidine derivatives as potent histone lysine demethylases (KDM) inhibitors and apoptosis inducers. Metwally NH; Mohamed MS; Ragb EA Bioorg Chem; 2019 Jul; 88():102929. PubMed ID: 31015179 [TBL] [Abstract][Full Text] [Related]
51. Design and synthesis of novel 2,3-dihydropyrazino[1,2-a]indole-1,4-dione derivatives as antiproliferative EGFR and BRAF Al-Wahaibi LH; Gouda AM; Abou-Ghadir OF; Salem OIA; Ali AT; Farghaly HS; Abdelrahman MH; Trembleau L; Abdu-Allah HHM; Youssif BGM Bioorg Chem; 2020 Nov; 104():104260. PubMed ID: 32920363 [TBL] [Abstract][Full Text] [Related]
52. Cytotoxicity, Docking Study of New Fluorinated Fused Pyrimidine Scaffold: Thermal and Microwave Irradiation Synthesis. Alnaja AMA; Farghaly TA; El-Zahabi HSA; Shaaban MR Med Chem; 2021; 17(5):501-518. PubMed ID: 31840613 [TBL] [Abstract][Full Text] [Related]
53. Novel molecular discovery of promising amidine-based thiazole analogues as potent dual Matrix Metalloproteinase-2 and 9 inhibitors: Anticancer activity data with prominent cell cycle arrest and DNA fragmentation analysis effects. Omar AM; Bajorath J; Ihmaid S; Mohamed HM; El-Agrody AM; Mora A; El-Araby ME; Ahmed HEA Bioorg Chem; 2020 Aug; 101():103992. PubMed ID: 32554279 [TBL] [Abstract][Full Text] [Related]
54. Development of pyrolo[2,3-c]pyrazole, pyrolo[2,3-d]pyrimidine and their bioisosteres as novel CDK2 inhibitors with potent in vitro apoptotic anti-proliferative activity: Synthesis, biological evaluation and molecular dynamics investigations. Azmy EM; Hagras M; Ewida MA; Doghish AS; Gamil Khidr E; El-Husseiny AA; Gomaa MH; Refaat HM; Ismail NSM; Nassar IF; Lashin WH Bioorg Chem; 2023 Oct; 139():106729. PubMed ID: 37467621 [TBL] [Abstract][Full Text] [Related]
56. Design, synthesis, and molecular docking studies of novel pomalidomide-based PROTACs as potential anti-cancer agents targeting EGFR O Aboelez M; Belal A; Xiang G; Ma X J Enzyme Inhib Med Chem; 2022 Dec; 37(1):1196-1211. PubMed ID: 35470756 [TBL] [Abstract][Full Text] [Related]
57. Synthesis and biological evaluation of irreversible EGFR tyrosine kinase inhibitors containing pyrido[3,4-d]pyrimidine scaffold. Zhang H; Wang J; Zhao HY; Yang XY; Lei H; Xin M; Cao YX; Zhang SQ Bioorg Med Chem; 2018 Jul; 26(12):3619-3633. PubMed ID: 29853340 [TBL] [Abstract][Full Text] [Related]
58. Design, synthesis, and SAR studies of novel 4-methoxyphenyl pyrazole and pyrimidine derivatives as potential dual tyrosine kinase inhibitors targeting both EGFR and VEGFR-2. El-Naggar AM; Hassan AMA; Elkaeed EB; Alesawy MS; Al-Karmalawy AA Bioorg Chem; 2022 Jun; 123():105770. PubMed ID: 35395446 [TBL] [Abstract][Full Text] [Related]
59. Synthesis and antitumor evaluation of novel 4-anilino-7,8-dihydropyrido[4,3-d]pyrimidine-6(5H)-carboxylate derivatives as potential EGFR inhibitors. Zhang D; Yan Y; Jin G; Liu B; Ma X; Han D; Jia X Arch Pharm (Weinheim); 2018 Sep; 351(9):e1800110. PubMed ID: 30048007 [TBL] [Abstract][Full Text] [Related]
60. Design, synthesis and biological evaluation of a new series of thiazolyl-pyrazolines as dual EGFR and HER2 inhibitors. Sever B; Altıntop MD; Radwan MO; Özdemir A; Otsuka M; Fujita M; Ciftci HI Eur J Med Chem; 2019 Nov; 182():111648. PubMed ID: 31493743 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]